Not yet recruiting
FirST Lines of Biologics in pAtients With ulceRaTivE Colitis: a Randomised Controlled Trial
NCT07576452· Phase 4· University Hospital, Clermont-Ferrand· Source
Not yet recruiting
Efficacy of Upadacitinib Re-induction Therapy in Patients With Ulcerative Colitis Who Lost Response to 30 mg Maintenance Dose
NCT07700446· Phase 4· Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives· Source
Not yet recruiting
A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity
NCT07861100· Phase 3· Novo Nordisk A/S· Source
Not yet recruiting
Evaluation of the Efficacy and Safety of Bimekizumab (BZK) or Adalimumab (ADA) in the Treatment of Anterior Chest Wall Pain Associated With Active Axial Spondyloarthritis Refractory to NSAIDs With Hypothesis of Superiority of Bimekizumab
NCT07836283· Phase 3· University Hospital, Rouen· Source
Recruiting
A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D–Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)
2025-525009-18-00· Phase 3· Incyte Corp.· Source
Not yet recruiting
BETARGET : Randomized trial of individualizing BETA-lactam taRGET combining therapeutic drug monitoring, minimal inhibitory concentration and model-based dose adjustment, in Intensive Care Units patients with gram negative bacilli infection
2025-522819-42-01· Phase 4· Centre Hospitalier Universitaire De Rennes· Source
Recruiting
PROlonged Corticosteroid Treatment or N-ACetylcysteine for Severe Alcoholic Hepatitis
NCT06956482· Phase 3· University Hospital, Lille· Source
Recruiting
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
NCT07567001· Phase 3· Novo Nordisk A/S· Source
Recruiting
Efficacy of Early Continuous Infusion of HSS on the Neurological Outcome at 6 Months in TBI Patients.
NCT07319208· Phase 3· Nantes University Hospital· Source
Active, not recruiting
Evaluation of efficacy and safety of early in hospital initiation of inclisiran treatment in patients with acute coronary syndromes
2025-521670-34-00· Phase 3· Novartis Pharma AG· Source
Not yet recruiting
A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with psoriatic arthritis (PsA)
2025-522471-28-00· Phase 3· MoonLake Immunotherapeutics AG· Source
Recruiting
A Study of the Efficacy and Safety of Danicamtiv in Participants with Symptomatic Genetic and Familial Dilated Cardiomyopathy.
2025-522553-19-00· Phase 2/3· Kardigan Inc.· Source
Recruiting
Safety of Atezolizumab-Bevacizumab in Liver Transplanted Patients With Advanced Hepatocellular Carcinoma
NCT06254248· Phase 2· Assistance Publique - Hôpitaux de Paris· Source
Recruiting
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF)
2024-516654-22-00· Phase 3· Amgen Inc.· Source
Active, not recruiting
A Phase 2 Multicenter, Randomized, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis
2024-519291-11-00· Phase 2· AbbVie Deutschland GmbH & Co. KG· Source
Recruiting
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT07064473· Phase 3· Boehringer Ingelheim· Source
Recruiting
TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
NCT07052903· Phase 3· Alnylam Pharmaceuticals· Source
Recruiting
JAK Inhibitor Dose TAPering Strategy Study
NCT06687551· Phase 4· University Hospital, Toulouse· Source
Recruiting
A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)
NCT06764615· Phase 2· Takeda· Source
Recruiting
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
NCT06819891· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo in participants aged 18 years and over with active psoriatic arthritis who are naive to biologic DMARDs
2024-516213-20-00· Phase 3· MoonLake Immunotherapeutics AG· Source
Active, not recruiting
A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo and risankizumab (active reference arm) in participants aged 18 years and over with active psoriatic arthritis and antiTNFα inadequate response.
2024-516219-25-00· Phase 3· MoonLake Immunotherapeutics AG· Source
Recruiting
An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis
NCT06668181· Phase 3· UCB Biopharma SRL· Source
Not yet recruiting
Stop Treatment in gout
2024-515714-40-00· Phase 2· Assistance Publique Hopitaux De Paris· Source
Not yet recruiting
Corticoid Therapy in Acute Myocarditis
NCT06522100· Phase 3· Assistance Publique - Hôpitaux de Paris· Source
Recruiting
Design and Evaluation of an Individualized Biodrug Tapering Strategy Based on Biodrug Dosage: the MONITORA Study
NCT06528431· Phase 4· Centre Hospitalier Universitaire de Saint Etienne· Source
Active, not recruiting
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06588855· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
Effect of Influenza Vaccination on Global Systemic Inflammatory Markers in Patients With Stable Coronary Artery Disease - Randomized Delayed-Start Pilot Trial
2024-514543-28-00· Phase 2· Centre Hospitalier Regional Universitaire De Tours· Source
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy
NCT06481891· Phase 3· Lexicon Pharmaceuticals· Source
Recruiting
Colchicine Versus Placebo in Acute Myocarditis Patients
NCT05855746· Phase 3· Assistance Publique - Hôpitaux de Paris· Source
Active, not recruiting
Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)
NCT06331312· Phase 3· Novartis Pharmaceuticals· Source
Recruiting
Neoadjuvant Chemotherapy for Obstructive Colon cancER First Treated by cOlostomy
NCT06107920· Phase 3· University Hospital, Rouen· Source
Recruiting
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
NCT06233461· Phase 2· Takeda· Source
Active, not recruiting
The BD Liverty™ TIPS Stent Graft Study
NCT05711316· C. R. Bard· Source
Active, not recruiting
A Study of Secukinumab to Evaluate Maintenance of Response in Participants With Non-radiographic Axial Spondyloarthritis Who Achieved Remission
NCT05622708· Phase 4· Novartis Pharmaceuticals· Source
Active, not recruiting
A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma
NCT05625399· Phase 3· Bristol-Myers Squibb· Source
Active, not recruiting
Pulmonary Embolism International THrOmbolysis Study-3
NCT04430569· Phase 3· Assistance Publique - Hôpitaux de Paris· Source
Active, not recruiting
Combination of Baricitinib and Anti-TNF in Rheumatoid Arthritis
NCT04870203· Phase 3· University Hospital, Bordeaux· Source
Active, not recruiting
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs
NCT04908202· Phase 3· Bristol-Myers Squibb· Source
Active, not recruiting
OSE2101+FOLFIRI, or FOLFIRI Maintenance After FOLFIRINOX-based Induction Therapy in Advanced or Metastatic PDAC
NCT03806309· Phase 2· GERCOR - Multidisciplinary Oncology Cooperative Group· Source
Active, not recruiting
Double blind, multicentric, randomized, placebo-controlled trial, evaluating the efficacy of 24-month of bezafibrate in primary sclerosing cholangitis with persistent cholestasis despite ursodeoxycholic acid therapy (BEZASCLER
NCT04309773· Phase 3· Assistance Publique Hopitaux De Paris· Source
Completed
USTekinumab in Fistulising Perianal Crohn's Disease (USTAP)
NCT04496063· Phase 4· Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives· Source
Recruiting
Chemotherapy For Metastatic Grade 3 Poorly Differentiated NEuroendocrine Carcinoma Of GastroEnteroPancreatic And Unknown Primary
NCT04325425· Phase 2· Centre Hospitalier Universitaire Dijon· Source
Recruiting
Non Inferiority Study of Preoperative Chemotherapy Without Pelvic Irradiation for Rectal Cancer
NCT03875781· Phase 3· Assistance Publique - Hôpitaux de Paris· Source
Active, not recruiting
Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib
NCT03235245· Phase 2· European Organisation for Research and Treatment of Cancer - EORTC· Source
Completed
LEAn Body Mass Normalization of OXaliplatin Based Chemotherapy
NCT03255434· Phase 2· Institut du Cancer de Montpellier - Val d'Aurelle· Source
Active, not recruiting
Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/1325-MG/KEYNOTE-054)
NCT02362594· Phase 3· Merck Sharp & Dohme LLC· Source